



Albiglutide (Eperzan[®]) powder and solvent for solution for injection

GlaxoSmithKline

June 2014

Statement of Advice

In the absence of a submission from the holder of the marketing authorisation, albiglutide (Eperzan[®]) cannot be endorsed for use within NHS Wales for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as: monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance; or add-on combination therapy in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

Advice context:

The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Care Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intend to publish final technology appraisal advice for the same product within twelve months of the projected Form B submission date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

The above medicine cannot be endorsed for use within NHS Wales as a technology appraisal by NICE or AWMSG has not been undertaken. The medicine should NOT be prescribed routinely within NHS Wales for the indication stated above.

In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This statement will be removed on receipt of a submission (i.e. the full submission [Forms A and B] or limited submission [Forms A and C]) or when final technology appraisal advice from NICE becomes available.